1. Metabolic Enzyme/Protease
  2. Xanthine Oxidase
  3. AA 193

AA 193 is an orally active uricosuric agent. AA 193 inhibits the net reabsorption of uric acid in nephrons, regulates the renal reabsorption process of filtered uric acid, promotes uric acid excretion in a dose-dependent manner, and reduces serum uric acid levels. AA 193 mildly inhibits the activity of xanthine dehydrogenase (XDH). AA 193 can be used in studies related to hyperuricemia.

Para uso exclusivo en investigación. No vendemos a pacientes.

AA 193

AA 193 Estructura química

No. CAS : 107804-48-8

Tamaño Stock
50 mg   Obtener un presupuesto  
100 mg   Obtener un presupuesto  
250 mg   Obtener un presupuesto  

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Top Publications Citing Use of Products
  • Actividad biológica

  • Pureza y Documentación

  • Referencias

  • Revisión del cliente

Descripciòn

AA 193 is an orally active uricosuric agent. AA 193 inhibits the net reabsorption of uric acid in nephrons, regulates the renal reabsorption process of filtered uric acid, promotes uric acid excretion in a dose-dependent manner, and reduces serum uric acid levels. AA 193 mildly inhibits the activity of xanthine dehydrogenase (XDH). AA 193 can be used in studies related to hyperuricemia[1][2].

In Vitro

AA 193 (1 mM; 20 min) has no effect on uricase activity in the lysosomal fraction of rat liver homogenate[1].
AA 193 (0.2-1 mM; 20 min) shows no effect on xanthine dehydrogenase activity in the cytosolic fraction of rat liver homogenate at a concentration of 0.2 mM, while 1 mM AA-193 slightly inhibits the activity of this enzyme[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

AA-193 (20-100 mg/kg; p.o.; once daily; for 7 consecutive days) maintains dose-dependent uricosuric activity without altering plasma uric acid levels after 7 consecutive days of daily oral administration in normal rats[1].
AA-193 (20-100 mg/kg; p.o.; once daily; for 7 consecutive days) exerts dose-dependent urate-lowering activity in hyperuricemic rats[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Wistar-Immamichi (8-week-old male, normal, fed standard diet pellet CE-2)[1]
Dosage: 20 mg/kg; 50 mg/kg; 100 mg/kg
Administration: p.o.; daily; 7 days
Result: Increased 24-hour urate excretion by 16.9% (20 mg/kg), 24.4% (50 mg/kg), and 25.0% (100 mg/kg) compared to vehicle control after first administration.
Maintained dose-dependent uricosuric activity over 7 consecutive administrations.
Did not significantly alter plasma urate concentrations throughout the study.
Increased plasma allantoin by 11.4% in the 100 mg/kg group on day 7, while urinary and plasma allantoin levels were largely unchanged otherwise.
Increased fractional excretion of urate at 50 mg/kg, with peak responses occurring 2 hours after administration, correlating with plasma AA-193 concentrations (57.1 μg/mL at 2 hours, 21.1 μg/mL at 8 hours on day 1, undetectable by 24 hours).
Showed similar plasma AA-193 concentration time course on day 1 and day 7.
Animal Model: Wistar-Immamichi (8-week-old male, hyperuricemic, fed standard diet pellet CE-2 blended with 2.5% oxonate potassium salt for days 1 to 8)[1]
Dosage: 20 mg/kg; 50 mg/kg; 100 mg/kg
Administration: p.o.; daily; 7 days
Result: Increased urate excretion rate at all doses.
Caused a dose-dependent decrease in plasma urate levels, with a significant 18.2% reduction in the 100 mg/kg group on day 7 compared to vehicle control.
Left plasma and urinary allantoin levels unchanged.
Increased fractional excretion of urate at 50 mg/kg, mirroring the relationship seen in normal rats.
Resulted in plasma urate levels and urate excretion rates 6 to 10 times higher than in normal rats, while fractional excretion of urate and inulin clearance values were comparable to normal rats.
Peso molecular

315.71

Fòrmula

C16H10ClNO4

No. CAS
SMILES

O=C(C1OC2=C(C1)C3=C(C(C4=CC=CC=C4)=NO3)C=C2Cl)O

Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureza y Documentación
Referencias
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Calculadora de molaridad

  • Calculadora de dilución

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Productos vistos recientemente:

Consulta en línea

Your information is safe with us. * Required Fields.

Nombre del producto

 

Requested Quantity *

Nombre del solicitante *

 

Saludo

Direcciòn del E-mail *

 

Número de teléfono *

Department

 

Nombre de la Organizaciòn *

City

Provincia

Country or Region *

     

Observaciones

Consulta para venta a granel

Inquiry Information

Nombre del producto:
AA 193
Cat. No.:
HY-106300
Cantidad:
MCE Japan Authorized Agent: